In a regulatory filing, ANI Pharmaceuticals CFO Stephen Carey disclosed the sale of 17,639 common shares of the company on August 14 at a price of $61.37 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $72 from $62 at Guggenheim
- ANI raises FY23 adjusted EPS view to $3.62-$4.11 from $2.99-$3.45
- ANI Pharmaceuticals reports Q2 adjusted EPS $1.28, consensus 68c
- ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
- ANIP Earnings this Week: How Will it Perform?
